Document Detail


Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts.
MedLine Citation:
PMID:  20651372     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain. MATERIALS AND METHODS: The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats. RESULTS: MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs. CONCLUSION: MPNPs efficiently delivered paclitaxel into brain glioma by magnetic targeting and enhance its antitumor activity. They are promising for local chemotherapy for malignant glioma.
Authors:
Ming Zhao; Chao Liang; Anmin Li; Jin Chang; Hanjie Wang; Runmin Yan; Jiajing Zhang; Junli Tai
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  30     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2217-23     Citation Subset:  IM    
Affiliation:
Department of Neurosurgery, First Affiliated Hospital of PLA General Hospital, 51 Fucheng Road, Haidian District, Beijing, 100048 PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents, Phytogenic / administration & dosage*
Brain Neoplasms / drug therapy*,  mortality,  pathology
Cell Line, Tumor
Cerebral Cortex / metabolism
Glioma / drug therapy*,  mortality,  pathology
Humans
Magnetics*
Nanoparticles / administration & dosage*
Paclitaxel / administration & dosage*,  chemistry,  metabolism
Rats
Rats, Sprague-Dawley
Solubility
Xenograft Model Antitumor Assays
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.
Next Document:  Promoter Polymorphisms and Methylation of E-Cadherin (CDH1) and KIT in Gastric Cancer Patients from ...